Loading…
BioLineRx Ltd. is projected to rise to $3.57 by 2027, a +6% move from its current price of $3.37. BLRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.22 | $3.37 | $3.53 | +0.01% |
| May 30 | $3.16 | $3.37 | $3.60 | +0.02% |
| May 31 | $3.11 | $3.37 | $3.66 | +0.03% |
| Jun 1 | $3.07 | $3.37 | $3.70 | +0.04% |
| Jun 2 | $3.04 | $3.37 | $3.74 | +0.05% |
| Jun 3 | $3.01 | $3.37 | $3.78 | +0.06% |
| Jun 4 | $2.98 | $3.37 | $3.82 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.98 | $3.37 | $3.82 | +0.07% |
| Week 2 | $2.83 | $3.37 | $4.02 | +0.14% |
| Week 3 | $2.73 | $3.38 | $4.18 | +0.21% |
| Week 4 | $2.64 | $3.38 | $4.33 | +0.27% |
| Week 5 | $2.57 | $3.38 | $4.46 | +0.34% |
| Week 6 | $2.50 | $3.38 | $4.58 | +0.41% |
| Week 7 | $2.44 | $3.39 | $4.70 | +0.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioLineRx Ltd. is a biopharmaceutical company that develops and commercializes therapeutics for oncology and rare diseases. Its pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
This description summarizes the company’s focus, pipeline, and corporate background based on the supplied facts.
BioLineRx Ltd. trades under symbol BLRX and has a current price of $3.37. Its market capitalization is $15.16M and it is ranked 4976. The forecast implies a long-run upside with the 2030 average price at $4.73 and the 2050 average price at $18.29, with a max of $42.07 in 2050 and a min of $8.23 in 2050, highlighting substantial long-term upside potential.
The 2030 max price is $7.90 and the 2030 min is $3.06, with a 40.4% ROI for that year. The near term has shown a 30-day trading range of $2.48 to $4.59, illustrating volatility within a relatively tight band around the current price.
A major floor 45.1% below — a decisive break under it would weaken the trend.
The nearest floor, 33.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 22.6% above — clearing it would confirm fresh momentum.
Key BLRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BLRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.04 | Buy | $3.12 | Buy |
| MA 10 | $2.98 | Buy | $3.03 | Buy |
| MA 20 | $3.01 | Buy | $2.93 | Buy |
| MA 50 | $2.62 | Buy | $2.79 | Buy |
| MA 100 | $2.75 | Buy | $2.86 | Buy |
| MA 200 | $3.16 | Buy | $3.72 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.69 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 165.29 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 9.77 | Buy |
| Bollinger %B (20,2) | 0.99 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.68 | Buy |
| Awesome (5,34) | 0.31 | Buy |
| Ultimate (7,14,28) | 62.17 | Neutral |
| Momentum (10) | 0.26 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 3.21 | Buy |
| ADX (14) | 18.72 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is bullish, supported by the sentiment label and momentum indicators. RSI(14) is 60, placing momentum in a positive zone. The stock’s short-term trend is influenced by the SMA50 at $2.62 and the SMA200 at $3.16, with a defined support at $2.23 and resistance at $3.37.
The 30-day range has traded from $2.48 to $4.59, and the stock exhibits notable near-term volatility, consistent with an active small-cap profile (annualized volatility 90%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.18 | $3.37 | $4.46 | 0% | Neutral | |
| $2.64 | $3.57 | $5.21 | +6% | Neutral | |
| $2.52 | $3.59 | $5.54 | +6% | Neutral | |
| $2.19 | $3.25 | $5.24 | -4% | Neutral | |
| $3.06 | $4.73 | $7.90 | +40% | Bullish | |
| $3.60 | $5.77 | $9.94 | +71% | Bullish | |
| $3.38 | $5.61 | $9.93 | +66% | Bullish | |
| $3.47 | $5.95 | $10.81 | +77% | Bullish | |
| $2.91 | $5.15 | $9.57 | +53% | Bullish | |
| $3.07 | $5.61 | $10.64 | +66% | Bullish | |
| $3.71 | $7.85 | $16.25 | +133% | Bullish | |
| $8.23 | $18.29 | $42.07 | +443% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.18 | $3.37 | $4.02 | +0.00% |
| June 2026 | $2.96 | $3.53 | $4.35 | +4.64% |
| July 2026 | $2.81 | $3.40 | $4.28 | -3.58% |
| August 2026 | $2.66 | $3.26 | $4.18 | -4.08% |
| September 2026 | $2.71 | $3.35 | $4.36 | +2.85% |
| October 2026 | $2.71 | $3.37 | $4.44 | +0.60% |
| November 2026 | $2.58 | $3.24 | $4.31 | -4.07% |
| December 2026 | $2.62 | $3.32 | $4.46 | +2.47% |
Click any year to see its month-by-month BLRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BLRX is projected to trade between $2.18 and $4.46, averaging $3.37 — a potential gain of 0% from today's $3.37. A consolidation phase looks the most probable path here.
BioLineRx Ltd.'s 2027 outlook centres on $3.57, within a $2.64 to $5.21 range. That is up +6% on the projected 2026 average. That marks a +6% change versus current levels. Price action looks broadly range-bound.
By 2028, BLRX could reach as high as $5.54, with a base case around $3.59 and support toward $2.52 — roughly +6% from $3.37. A consolidation phase looks the most probable path here.
Expect BLRX to range from $2.19 to $5.24 through 2029. The $3.25 average target implies a -4% move from current prices. That is -9% versus the projected 2028 average. Price action looks broadly range-bound.
The BLRX price prediction for 2030 points to an average of $4.73 (low $3.06, high $7.90) — a potential gain of +40% on today's $3.37. Buyers look set to stay in control over this stretch.
In 2031, BLRX is projected to trade between $3.60 and $9.94, averaging $5.77 — a potential gain of +71% from today's $3.37. That is up +22% on the projected 2030 average. Momentum favours further upside here.
BioLineRx Ltd.'s 2032 outlook centres on $5.61, within a $3.38 to $9.93 range. That is -3% versus the projected 2031 average. That marks a +66% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BLRX could reach as high as $10.81, with a base case around $5.95 and support toward $3.47 — roughly +77% from $3.37. Momentum favours further upside here.
Expect BLRX to range from $2.91 to $9.57 through 2034. The $5.15 average target implies a +53% move from current prices. That is -13% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The BLRX price prediction for 2035 points to an average of $5.61 (low $3.07, high $10.64) — a potential gain of +66% on today's $3.37. Momentum favours further upside here.
In 2040, BLRX is projected to trade between $3.71 and $16.25, averaging $7.85 — a potential gain of +133% from today's $3.37. That is up +40% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioLineRx Ltd.'s 2050 outlook centres on $18.29, within a $8.23 to $42.07 range. That is up +133% on the projected 2040 average. That marks a +443% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BLRX today (≈ 296.735905 BLRX) could be worth
$5,427.29
+$4,427.29 (+443%) by 2050 · US Dollar
Based on the average projected BLRX price of $18.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BLRXwould be worth at today's price.
$1,000 invested in BLRX on May 27, 2025 (≈ 271.739126 BLRX) would be worth
$915.76
-$84.24 (-8.4%) today · 0.92× · US Dollar
Based on a BLRX entry price of $3.68 vs. today's $3.37.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.75 | $1,225.45 | +22.5% |
| 1 month ago | $2.23 | $1,511.21 | +51.1% |
| 3 months ago | $2.88 | $1,170.14 | +17.0% |
| 6 months ago | $3.47 | $971.18 | -2.9% |
| 1 year ago | $3.68 | $915.76 | -8.4% |
| All time (5.0y) ago | $112 | $30.09 | -97.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BLRX forecast.
Our base-case forecast reaches $6.70 around 2040.
Implied market cap at $6.70: $29.15M
From 2030 onward, the forecast turns bullish, with an average price of $4.73 in 2030 and a maximum of $7.90, corresponding to a 40.4% ROI and a bullish sentiment. The outlook remains positive through 2040, with an average of $7.85, a maximum of $16.25, and a 133% ROI.
By 2050, the average price is projected at $18.29, with a max of $42.07 and a 442.7% ROI, continuing the bullish trajectory.
Earlier years show more modest or mixed signals: 2026 average $3.37 (ROI 0), 2027 average $3.57 (ROI 5.9%), 2028 average $3.59 (ROI 6.4%), and 2029 average $3.25 (ROI -3.5%). These figures illustrate evolving upside potential set against some near-term volatility and uncertainty.
Tap a question to reveal the answer.
The 2030 forecast lists min $3.06, avg $4.73, max $7.90 with an ROI of 40.4% and sentiment BULLISH.
The long-term forecast shows bullish sentiment with potential upside (2050 avg $18.29, max $42.07 and ROI 442.7%), but near-term years (2026-2029) show neutral to negative readings (e.g., 2029 ROI -3.5%), so outcomes are uncertain and these are estimates, not guarantees.
Yes. The 2030 forecast includes a max of $7.90, with an average of $4.73 and a 40.4% ROI, indicating possible upside within that year.
Current price is $3.37 and market cap is $15.16M.
For 2040, the average is $7.85 with a max of $16.25 and ROI of 133%; for 2050, the average is $18.29 with a max of $42.07 and ROI of 442.7%, with bullish sentiment in both years.
BioLineRx Ltd. Community Discussion
0Share your BioLineRx Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.